The Food and Drug Administration (FDA) is proposing significant changes to the procedures for testing and approving vaccines, following unverified claims that mRNA-based COVID-19 vaccines led to the deaths of at least 10 children. This plan was outlined in a memo dated November 28, 2025, which several news outlets have reviewed and discussed.
The memo, written by Vinay Prasad, the FDA’s leading vaccine regulator, cites an internal review attributing the children’s deaths to myocarditis, an inflammation of the heart muscle. However, it lacks any evidence linking the vaccines directly to these fatalities, despite the deaths being logged in the Vaccine Adverse Event Reporting System (VAERS).
As a pediatric cardiologist with a focus on the heart-related side effects of COVID-19 vaccines, I acknowledge the gravity of allegations regarding child deaths due to unsafe vaccines. Current studies indicate that major side effects like myocarditis are rare, and severe outcomes are even rarer. Nevertheless, I am open to new evidence that might alter this view.
Without solid justification and substantiated evidence, restricting access to approved vaccines and altering established testing procedures could have dire consequences. These changes could hinder patient access, impede manufacturers, and deepen public skepticism toward vaccines and health authorities.
It is crucial for the public to understand how vaccine safety is typically evaluated. The FDA’s memo claims that the children’s deaths were directly linked to COVID-19 vaccinations. It’s heartbreaking for any child to die from a routine vaccine. Health professionals must strive for the highest standards in investigating such events. If the FDA possesses evidence indicating that global health authorities have overlooked significant child mortality due to vaccine-induced myocarditis, I would expect that even the most vaccine-enthusiastic doctors would pay attention. However, such evidence has yet to be presented.
While a VAERS report can initiate a review, it alone cannot determine a causal link between a vaccine and a death. To establish causation, FDA staff must correlate the VAERS reports with clinical assessments and other safety monitoring data, including insurance claim data and signals tracked in electronic medical records.
It is well-documented that the majority of deaths recorded in VAERS among children who have received vaccinations have been misattributed to vaccines, either inadvertently or, in some cases, intentionally by anti-vaccine activists.
Moreover, Vinay Prasad has expressed concern that the actual rate of severe cardiac side effects post-vaccination is likely underestimated, advocating for stricter vaccine regulations. He mentioned a risk of 27 cases of myocarditis per million young men following vaccination, although a 2024 review indicated the actual figure might be closer to 20 cases per million. Importantly, that same study found unvaccinated individuals faced a higher risk of heart problems after COVID-19 infection, and those who developed myocarditis post-vaccination experienced fewer complications than those who contracted it post-infection.
The U.S. vaccine safety monitoring system has proven effective, identifying real dangers, including blood clotting risks associated with certain COVID-19 vaccines. In April 2021, the FDA advised pausing the use of these vaccines based on findings from VAERS data. Deaths attributed to myocarditis due to COVID-19 vaccination are rare, and proving such cases necessitates extensive evidence.
Another significant concern is the proposed shift toward requiring more placebo-controlled trials for vaccine approval, a change deemed impractical. Vaccines need annual updates to match viral mutations, and conducting new placebo trials each year could render vaccines obsolete by the time they are approved. This could result in wasted resources and valuable time.
Assessing vaccine-related myocarditis involves meticulously designed clinical trials that are significantly larger than those previously conducted for COVID-19 vaccines. Requiring such extensive studies could delay vaccine availability and prolong public health risks.
It’s essential to thoroughly and transparently investigate any claims of vaccine-related harm without unjustifiably hindering vaccine access, as doing so may lead to a meaningful decline in public trust.
Additionally, to evaluate the risks associated with vaccination accurately, one must compare adverse effects to the consequences of the illness that the vaccines are designed to prevent. Data indicates that COVID-19 poses a far greater risk, having caused over 800 pediatric deaths in the U.S. between August 2021 and July 2022. Conversely, verified deaths from COVID-19 vaccines in children are exceedingly few, and COVID-19 itself leads to more heart-related side effects than the vaccine does.
There is extensive evidence that COVID-19 vaccination significantly reduces hospitalization risk and the chance of severe illness in adolescents. Studies show that vaccination diminishes the risk of developing long COVID. Reporting only the risks associated with vaccines without acknowledging their benefits fails to provide a comprehensive view of public health outcomes.
Original Source: https://nenow.in/lifestyle/fda-claims-on-covid-19-vaccine-safety-are-unsupported-by-reliable-data-and-could-severely-hinder-vaccine-access.html
Category: Lifestyle,Top News
Tags:
Publish Date: 2025-12-06 23:08:00
